<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Neurometrix Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/neurometrix-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(NURO) NeuroMetrix Partners for Diabetes</title>
		<link>http://www.stockbloghub.com/2011/06/20/nuro-neurometrix-partners-for-diabetes/76607</link>
		<comments>http://www.stockbloghub.com/2011/06/20/nuro-neurometrix-partners-for-diabetes/76607#comments</comments>
		<pubDate>Mon, 20 Jun 2011 16:18:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Neurometrix Inc]]></category>
		<category><![CDATA[NURO]]></category>
		<category><![CDATA[Target Corporation]]></category>
		<category><![CDATA[TGT]]></category>
		<category><![CDATA[Wal-Mart Stores Inc.]]></category>
		<category><![CDATA[WMT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76607</guid>
		<description><![CDATA[Nerve testing devices maker NeuroMetrix (NURO) has partnered with Florida-based leading diabetes management products maker Nipro Diagnostics for its latest test, the NC-stat DPNCheck. The NC-stat DPNCheck test has been designed for evaluating systemic neuropathies such as diabetic peripheral neuropathy (“DPN”). Nipro Diagnostics, a wholly-owned subsidiary of Japan-based Nipro Corporation Inc, offers high-quality blood glucose monitoring products and systems globally. The collaboration (between NeuroMetrix and Nipro) will focus on evaluating the opportunities for the novel NC-stat DPNCheck test in the rapidly growing retail medical clinic market. DPN, a common and serious complication of diabetes, affects roughly 60%-70% of diabetics and may lead to foot ulcers and amputations. Currently, there is a lack of standardized test for DPN at the point-of-care, triggering a large unmet need. NC-stat DPNCheck is a modified ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/20/nuro-neurometrix-partners-for-diabetes/76607/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NURO) NeuroMetrix Files for Public Sale of 4.3 Million Shares</title>
		<link>http://www.stockbloghub.com/2009/12/28/nuro-neurometrix-files-for-public-sale-of-4-3-million-shares/23747</link>
		<comments>http://www.stockbloghub.com/2009/12/28/nuro-neurometrix-files-for-public-sale-of-4-3-million-shares/23747#comments</comments>
		<pubDate>Tue, 29 Dec 2009 01:33:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Neurometrix Inc]]></category>
		<category><![CDATA[NURO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23747</guid>
		<description><![CDATA[NeuroMetrix, Inc. (NURO) announced that it has filed paperwork to register roughly 4.3 million shares, which constitute approximately 20% of its common stock outstanding, for public sale. These shares are presently owned by one of the Waltham, Mass.-based NeuroMetrix’s largest shareholders, New York hedge fund manager Deerfield Management. The share registration for public sale conforms to the terms of the private financing agreement with Deerfield, and doesn’t indicate an unexpected exit or unloading of ownership on the part of Deerfield. As per the agreement, NeuroMetrix will not receive any proceeds from the public sale of these newly registered shares. Deerfield acquired NeuroMetrix’s common shares for $2 per share in Sept. 2009. The private placement generated a net $17.3 million for NeuroMetrix. NeuroMetrix designs, develops and sells proprietary medical devices to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/28/nuro-neurometrix-files-for-public-sale-of-4-3-million-shares/23747/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NURO) Court Dismisses NeuroMetrix Securities Class Action Lawsuit</title>
		<link>http://www.stockbloghub.com/2009/12/17/nuro-court-dismisses-neurometrix-securities-class-action-lawsuit/23143</link>
		<comments>http://www.stockbloghub.com/2009/12/17/nuro-court-dismisses-neurometrix-securities-class-action-lawsuit/23143#comments</comments>
		<pubDate>Fri, 18 Dec 2009 01:22:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Neurometrix Inc]]></category>
		<category><![CDATA[NURO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23143</guid>
		<description><![CDATA[NeuroMetrix, Inc. (NURO) reported that the United States District Court for the District of Massachusetts dismissed the consolidated federal securities class action lawsuit that had been pending against the company. The lawsuit was filed against NeuroMetrix and certain of its officers on behalf of a purported class of investors (‘the plaintiffs’) who had purchased the company’s common stock between Oct 27, 2005 and Feb 12, 2008. The allegation was that NeuroMetrix had violated the federal securities laws by providing false and misleading statements and failed to disclose material information in various Securities and Exchange Commission (SEC) filings. The United States District Court for the District of Massachusetts has dismissed the plaintiffs’ allegations in their entirety. However, the plaintiffs can appeal the Court’s decision. The Court’s actions provide a temporary relief ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/17/nuro-court-dismisses-neurometrix-securities-class-action-lawsuit/23143/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NURO) NeuroMetrix Inc Raises Funds</title>
		<link>http://www.stockbloghub.com/2009/09/09/nuro-neurometrix-inc-raises-funds/14710</link>
		<comments>http://www.stockbloghub.com/2009/09/09/nuro-neurometrix-inc-raises-funds/14710#comments</comments>
		<pubDate>Wed, 09 Sep 2009 21:30:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Neurometrix Inc]]></category>
		<category><![CDATA[NURO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14710</guid>
		<description><![CDATA[NeuroMetrix Inc. (NURO) entered into a private placement transaction with institutional investors for $18.68 million worth of its common stock. Per the agreement, the company will sell 8,816,521 shares and warrants to purchase up to 8,375,695 additional shares of common stock. Each unit, comprising a common stock and a warrant to buy 0.95 share, will carry a purchase price of $2.12. NeuroMetrix expects to close the offer later this week. The warrants will expire five years from their date of issuance. NeuroMetrix designs, develops and sells proprietary medical devices to diagnose neuropathies, which are disturbances of the nervous system. Principally, the company offers physicians an in-office diagnostic system named the NC-stat System. The NC-stat System enables physicians to make rapid and accurate diagnoses of peripheral neuropathies Incorporatedluding carpal tunnel syndrome, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/nuro-neurometrix-inc-raises-funds/14710/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

